Danaher Corporation $DHR Shares Bought by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its stake in Danaher Corporation (NYSE:DHR) by 7,466.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 669,181 shares of the conglomerate’s stock after purchasing an additional 660,337 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Danaher were worth $148,257,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Danaher during the second quarter worth about $10,492,520,000. Wellington Management Group LLP grew its stake in Danaher by 10.4% during the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after buying an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC acquired a new stake in Danaher during the second quarter worth about $1,456,317,000. Generation Investment Management LLP bought a new position in Danaher in the 2nd quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE bought a new position in Danaher in the 2nd quarter valued at about $993,846,000. Institutional investors own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DHR. Barclays boosted their target price on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Guggenheim raised their target price on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Evercore restated an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. Finally, UBS Group assumed coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Stock Up 0.8%

NYSE:DHR opened at $224.65 on Thursday. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market cap of $157.93 billion, a PE ratio of 39.90, a P/E/G ratio of 2.80 and a beta of 0.76. The firm’s 50 day simple moving average is $212.92 and its 200 day simple moving average is $195.39.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same period in the prior year, the company posted $0.77 EPS. The company’s revenue was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.